Am J Psychiatry 161:1709-1711, September 2004
© 2004 American Psychiatric Association
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Douglas L. Leslie, Ph.D., and
Robert A. Rosenheck, M.D.
OBJECTIVE: The purpose of the study was to determine the proportion of patients with schizophrenia with a stable regimen of antipsychotic monotherapy who developed diabetes or were hospitalized for ketoacidosis. METHOD: Patients with schizophrenia for whom a stable regimen of antipsychotic monotherapy was consistently prescribed during any 3-month period between June 1999 and September 2000 and who had no diabetes were followed through September 2001 by using administrative data from the Department of Veterans Affairs. Cox proportional hazards models were developed to identify the characteristics associated with newly diagnosed diabetes and ketoacidosis. RESULTS: Of the 56,849 patients identified, 4,132 (7.3%) developed diabetes and 88 (0.2%) were hospitalized for ketoacidosis. Diabetes risk was highest for clozapine (hazard ratio=1.57) and olanzapine (hazard ratio=1.15); the diabetes risks for quetiapine (hazard ratio=1.20) and risperidone (hazard ratio=1.01) were not significantly different from that for conventional antipsychotics. The attributable risks of diabetes mellitus associated with atypical antipsychotics were small, ranging from 0.05% (risperidone) to 2.03% (clozapine). CONCLUSIONS: Although clozapine and olanzapine have greater diabetes risk, the attributable risk of diabetes mellitus with atypical antipsychotics is small.
This article has been cited by other articles:
|
|
|
|
 
S. Park, S. Hong, J. Lee, S. Sung, and S. Kim
Chlorpromazine attenuates pancreatic {beta}-cell function and mass through IRS2 degradation, while exercise partially reverses the attenuation
J Psychopharmacol,
July 1, 2008;
22(5):
522 - 531.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Smith, D. Hopkins, R. C. Peveler, R. I. G. Holt, M. Woodward, and K. Ismail
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis
The British Journal of Psychiatry,
June 1, 2008;
192(6):
406 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Soumerai, F. Zhang, D. Ross-Degnan, D. E. Ball, R. F. LeCates, M. R. Law, T. E. Hughes, D. Chapman, and A. S. Adams
Use Of Atypical Antipsychotic Drugs For Schizophrenia In Maine Medicaid Following A Policy Change
Health Aff.,
May 1, 2008;
27(3):
w185 - w195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak
Rethinking Antipsychotic Formulary Policy
Schizophr Bull,
March 1, 2008;
34(2):
375 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. M. van Nimwegen, J. G. Storosum, R. M. E. Blumer, G. Allick, H. W. Venema, L. de Haan, H. Becker, T. van Amelsvoort, M. T. Ackermans, E. Fliers, et al.
Hepatic Insulin Resistance in Antipsychotic Naive Schizophrenic Patients: Stable Isotope Studies of Glucose Metabolism
J. Clin. Endocrinol. Metab.,
February 1, 2008;
93(2):
572 - 577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L Citrome, R. I. Holt, W. M Zachry, J. D Clewell, P. A Orth, J. L Karagianis, and V. P. Hoffmann
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Ann. Pharmacother.,
October 1, 2007;
41(10):
1593 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Holt
Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome
The British Journal of Diabetes & Vascular Disease,
September 1, 2006;
6(5):
199 - 204.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Citrome, A. Jaffe, J. Levine, and D. Martello
Incidence, Prevalence, and Surveillance for Diabetes in New York State Psychiatric Hospitals, 1997-2004
Psychiatr Serv,
August 1, 2006;
57(8):
1132 - 1139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Fulbright and K. T. Breedlove
Complete Resolution of Olanzapine-Induced Diabetic Ketoacidosis
Journal of Pharmacy Practice,
August 1, 2006;
19(4):
255 - 258.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. P. Reynolds and J. H. Thakore
Metabolic syndrome and schizophrenia * Author's reply:
The British Journal of Psychiatry,
January 1, 2006;
188(1):
86 - 87.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. G. Holt, C. Bushe, and L. Citrome
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
56 - 65.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. B. Dickerson, R. W. Goldberg, C. H. Brown, J. A. Kreyenbuhl, K. Wohlheiter, L. Fang, D. Medoff, and L. B. Dixon
Diabetes Knowledge Among Persons With Serious Mental Illness and Type 2 Diabetes
Psychosomatics,
October 1, 2005;
46(5):
418 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Leslie and R. A. Rosenheck
Pharmacotherapy and Health Care Costs Among Patients With Schizophrenia and Newly Diagnosed Diabetes
Psychiatr Serv,
July 1, 2005;
56(7):
803 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S Gill
Stable monotherapy with clozapine or olanzapine increases the incidence of diabetes mellitus in people with schizophrenia
Evid. Based Ment. Health,
February 1, 2005;
8(1):
24 - 24.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Diabetes Associated with Atypical Antipsychotic Drugs
Journal Watch Psychiatry,
November 18, 2004;
2004(1118):
7 - 7.
[Full Text]
|
|
|
|
|
|
|
Diabetes Associated with Atypical Antipsychotic Drugs
Journal Watch Gastroenterology,
October 26, 2004;
2004(1026):
7 - 7.
[Full Text]
|
|
|
|
|
|
|
Diabetes Associated with Atypical Antipsychotic Drugs
Journal Watch (General),
October 15, 2004;
2004(1015):
4 - 4.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
